After screening ∼5000 compounds, we identified two compounds that synergised with a sub-therapeutic dose of trametinib to reduce tumour size: the Polo-like kinase inhibitor, volasertib, and the serotonin receptor and diacyl glycerol kinase (DGK) inhibitor, ritanserin. This evidence concerns the gene DGKB and neoplasm.